Company intelligence / Profile preview

Guidon Pharmaceutics

Beijing, Beijing, Chinaguidonpharmaceutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Guidon Pharmaceutics is developing GD-iExo-003, an intravenous exosome therapy derived from human induced pluripotent stem cells for the treatment of acute ischemic stroke. The program is currently in Phase I clinical trials. The company has established itself as a leader in iPSC technology and neurodegenerative disease modeling, with multiple patents and recognition as a high-tech enterprise in China. No published clinical results are available yet; the lead asset remains early-stage but addresses significant unmet need with innovative modalities.

Therapeutic areas: Cardiovascular
Modalities: Exosomes derived from human induced pluripotent stem cells (iPSC)iPSCs and related cell-based technologies
Industry: Biotech

Drug pipeline

1 asset

GD-iExo-003

Partnerships

Beijing Konruns Pharmaceutical Co., Ltd. participated as an investor and holds a minority stake after a capital increase agreement

Beyond the preview

Go deeper on Guidon Pharmaceutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guidon Pharmaceutics.

Explore the full profile